Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT1A1 | P22309 | 3/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.45 |
| ▸ | MLNR | O43193 | 1/20 | 0.45 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | CCKAR | P32238 | 1/20 | 0.45 |
| ▸ | GHSR | Q92847 | 1/20 | 0.45 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.38 |
| ▸ | AGER | Q15109 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393562 | 0.87 | UGT1A1 (0.43) | UGT1A1OPRK1NR1I2MLNRSLCO2B1 | |
| SCHEMBL8152590 | 0.87 | UGT1A1 (0.43) | UGT1A1OPRK1NR1I2MLNRSLCO2B1 | |
| SCHEMBL12595685 | 0.87 | UGT1A1 (0.45) | UGT1A1OPRK1NR1I2MLNRSLCO2B1 | |
| SCHEMBL2177873 | 0.87 | UGT1A1 (0.43) | UGT1A1OPRK1NR1I2MLNRSLCO2B1 | |
| Hydrochloric Acid SCHEMBL1300940 | 0.86 | UGT1A1 (0.43) | UGT1A1OPRK1NR1I2MLNRSLCO2B1 | |
| Hydrochloric Acid SCHEMBL6156798 | 0.86 | UGT1A1 (0.43) | UGT1A1OPRK1NR1I2MLNRSLCO2B1 | |
| Hydrochloric Acid SCHEMBL30018372 | 0.86 | UGT1A1 (0.43) | UGT1A1OPRK1NR1I2MLNRSLCO2B1 | |
| SCHEMBL496176 | 0.84 | CSNK1E (0.51) | OPRK1CSNK1EKCNH2AGERMEN1 | |
| SCHEMBL8228791 | 0.83 | JAK1 (0.37) | UGT1A1OPRK1NR1I2MLNRSLCO2B1 | |
| Hydrochloric Acid SCHEMBL496241 | 0.83 | CSNK1E (0.50) | OPRK1CSNK1EKCNH2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071270-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180021436-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED Ph EFFECT | BRISTOL MYERS SQUIBB CO (US) | 2018-01-25 | — | — | US | disclosed |
| US-20150202191-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB CO (US) | 2015-07-23 | — | — | US | disclosed |
| US-20130266648-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL MYERS SQUIBB CO (US) | 2013-10-10 | — | — | US | disclosed |
| US-8513428-B2 | Process for preparing atazanavir bisulfate and novel forms | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110124689-A1 | PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-26 | — | — | US | disclosed |
| US-7838678-B2 | Process for preparing atazanavir bisulfate and novel forms | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| US-7829720-B2 | Process for preparing atazanavir bisulfate and novel forms | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100183715-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | Bristo-Meyers Squibb Company | 2010-07-22 | — | — | US | disclosed |
| US-20100178339-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-15 | — | — | US | disclosed |
| US-20090203630-A1 | PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183715-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | UGT1A1 970/4885OPRK1 1962/4885NR1I2 3899/4885 |
| US-20180071270-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | UGT1A1 970/4885OPRK1 1962/4885NR1I2 3899/4885 |
| US-20130266648-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | UGT1A1 970/4885OPRK1 1962/4885NR1I2 3899/4885 |
| US-20100178339-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | UGT1A1 970/4885OPRK1 1962/4885NR1I2 3899/4885 |
| US-20090203630-A1 | PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS | GTF3C3, PRSS3, GTF3C4 | UGT1A1 1255/4885OPRK1 2196/4885NR1I2 3857/4885 |
| US-20110124689-A1 | PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS | GTF3C3, PRSS3, GTF3C4 | UGT1A1 1255/4885OPRK1 2196/4885NR1I2 3857/4885 |
| US-20180021436-A1 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED Ph EFFECT | ACIN1, SAMHD1, ARSA | UGT1A1 2092/4885OPRK1 3056/4885NR1I2 3993/4885 |
| US-20150202191-A1 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR | ACIN1, ATAD5, PGA5 | UGT1A1 970/4885OPRK1 1962/4885NR1I2 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.